These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 23074173)

  • 21. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
    Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
    J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
    Jung KH; Noh JH; Kim JK; Eun JW; Bae HJ; Xie HJ; Chang YG; Kim MG; Park H; Lee JY; Nam SW
    J Cell Biochem; 2012 Jun; 113(6):2167-77. PubMed ID: 22492270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
    Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
    Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exjade (ICL 670): A new oral iron chelator.
    Agarwal MB
    J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
    Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
    Selig RA; White L; Gramacho C; Sterling-Levis K; Fraser IW; Naidoo D
    Cancer Res; 1998 Feb; 58(3):473-8. PubMed ID: 9458092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
    Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
    Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
    Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
    Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
    Loza-Rosas SA; Vázquez-Salgado AM; Rivero KI; Negrón LJ; Delgado Y; Benjamín-Rivera JA; Vázquez-Maldonado AL; Parks TB; Munet-Colón C; Tinoco AD
    Inorg Chem; 2017 Jul; 56(14):7788-7802. PubMed ID: 28644630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
    Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
    Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice.
    Wang YJ; Jeng JH; Chen RJ; Tseng H; Chen LC; Liang YC; Lin CH; Chen CH; Chu JS; Ho WL; Ho YS
    Mol Carcinog; 2002 Aug; 34(4):199-210. PubMed ID: 12203371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
    Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
    Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
    Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
    Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT; Olin BR
    Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cyclin D1 regulates lung cancer invasion and metastasis].
    Li ZL; Shao SH; Jiao F; Yue Z; Ma Y
    Sheng Li Xue Bao; 2012 Feb; 64(1):55-61. PubMed ID: 22348961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
    Darnell G; Richardson DR
    Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
    Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
    Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
    Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.